Sidebar: Biologics In The Spotlight: Novartis’ Canakinumab
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis' entry among the BLAs with a 2009 user fee goal, canakinumab, well illustrates the company's approach to biologics through the six-year-old Novartis Institute for Biomedical Research.
You may also be interested in...
Novartis Has Proof Of Concept For New R&D Model, And NMEs To Show It
Novartis showed off its new drug pipeline for the first time in three years Nov. 19, but the R&D day was as much about vindicating the novel research strategy it rolled out in 2002 as it was previewing the work in process.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product